AtriCure price target raised to $81 from $67 at Canaccord

Canaccord analyst William Plovanic raised the firm’s price target on AtriCure to $81 from $67 and keeps a Buy rating on the shares. The analyst updated his model to reflect the company’s Q4 preannouncement and 2023 guidance.